Projects / Programmes
| Code |
Science |
Field |
Subfield |
| 3.06.00 |
Medical sciences |
Cardiovascular system |
|
| Code |
Science |
Field |
| B001 |
Biomedical sciences |
General biomedical sciences |
| B220 |
Biomedical sciences |
Genetics, cytogenetics |
| B190 |
Biomedical sciences |
Clinical chemistry |
| B490 |
Biomedical sciences |
Haematology, extracellular fluids |
| B530 |
Biomedical sciences |
Cardiovascular system |
atherothrombosis, anticoagulant treatment, D-dimer, fibrinogen, fibrinolysis, haemostasis, heparin, marker of haemostatic system activation, mutation, obesity, plasminogen activator inhibitor, polymorphism, pothrombotic syndrome, prothrombin, prothrombin fragment 1+2, risk factor, thrombin-antithrombin complex, tissue plasminogen activator, thrombosis, thrombopihilia
Researchers (28)
Organisations (1)
Abstract
Presence of genetic risk factors (antithrombin, protein C and S deficiency, mutation in factor V and prothrombin gene) can explain development of deep vein thrombosis in about one third of consecutive patients. In the frame of the proposed project prevalence of prothrombin gene mutation in Slovene population will be investigated. Determination of coagulation activation markers (prothrombin fragment 1+2, thrombin-antithrombin complex and D-dimer) will be performed in order to elucidate if patients with deep vein thrombosis and genetic risk factors have enhanced coagulation. As new candidate genes for risk factors, fibrinogen polypeptide chains genes will be investigated.
Clinical diagnosis of deep vein thrombosis is uncertain, objective diagnosis with x-ray venography or ultrasound associated with risk for the patient, is expensive and time-consuming. Therefore, diagnostic scheme including coagulation activation markers for accurate and faster diagnosis will be evaluated.
Fibrinolysis is a natural defence mechanism againt development and expansion of thrombi. Obesity, an independent risk factor for atherothrombosis is associated with altered fibrinolysis. The role of adipose tissue in regulation of blood fibrinolytic activity will be investigated in subject during body weight loss. In obese subjects diurnal fluctuation of fibrinolitic inhibitor will be studied.
Standard heparin followed by oral anticoagulant treatment with coumarins is accepted treatment of deep vein thrombosis. Low molecular weight heparin, which become available recently, is considered as effective and safe as standard heparin. Anticoagulation effect of standard heparin will be monitored by a bedside method, which will be compared to accepted laboratory monitoring of treatment. Effect of low molecular weight heparin will be determined by an anti factor Xa assay in pregnant women with thrombosis. Accepted coumarin treatment will be compared to computer-assisted treatment, which enables constant evidence about patients state and current modification of dosage. Coumarin monitoring in specialized units will be compared to monitoring in units of primary care.
The main complication of deep vein thrombosis in the late phase of the disease is cronic vein insufficiency (post-thrombic syndrome), affecting about half of the patients. Factors, which influence the development of post-thrombic syndrome are not adequately studied. Therefore, recanalization will be estimated by ultrasound and associations between patient characteristics and development of this late complication studied.
